title: Resistance to ALK inhibitors: Pharmacokinetics, mutations or bypass signaling?
authors.affiliation: a Department of Medicine , Division of Hematology/Oncology, Beth Israel Deaconess Medical Center, Harvard Medical School , Boston , MA , USA.
authors.forename: Daniel B
authors.initials: DB
authors.lastname: Costa
mesh_terms: D002289:Carcinoma, Non-Small-Cell Lung; D019008:Drug Resistance, Neoplasm / Q000187:drug effects; D006801:Humans; D008175:Lung Neoplasms; D009154:Mutation / Q000187:drug effects; D047428:Protein Kinase Inhibitors; D011720:Pyrazoles; D020794:Receptor Protein-Tyrosine Kinases / Q000235:genetics*
chemical_list: D047428:Protein Kinase Inhibitors; D011720:Pyrazoles; D020794:Receptor Protein-Tyrosine Kinases
keywords: ALK; Anaplastic lymphoma kinase; STAT3; acquired resistance; alectinib; ceritinib; crizotinib; lung cancer